Squarepoint’s Vaccinex, Inc. Common Stock VCNX Stock Holding History

Squarepoint’s Portfolio VCNX Stock Details VCNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-193	Closed	-$84K	–	3725
2020 Q4	$84K	Buy	+193	New	+$80.8K	﹤0.01%	2745

Other funds holding VCNX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Oppenheimer & Co New York $9.37B AUM 36.4% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Squarepoint's VCNX Position: Q1 2021 in Review

Squarepoint sold out of Vaccinex, Inc. Common Stock (VCNX) in Q1 2021, closing a stake of 193 shares — an estimated $84K sold.

Squarepoint first reported a position in VCNX in Q4 2020 and held it in 1 quarter. The position peaked at $84K in Q4 2020. 26 funds tracked by Wall St. Rank hold VCNX as of Q1 2021.

Squarepoint reported no remaining Vaccinex, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
Squarepoint sold 193 Vaccinex, Inc. Common Stock shares in Q1 2021, an estimated $84K.
Squarepoint first reported a position in Vaccinex, Inc. Common Stock in Q4 2020 and held it in 1 quarter.
Squarepoint's Vaccinex, Inc. Common Stock position peaked at $84K in Q4 2020.
26 funds tracked by Wall St. Rank held Vaccinex, Inc. Common Stock as of Q1 2021.

Based on Squarepoint's 13F filing for Q1 2021, filed 17 May 2021.